Dynavax Technologies Corporation (DVAX) Shares Gap Up to $21.15

Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) gapped up prior to trading on Tuesday . The stock had previously closed at $22.30, but opened at $21.15. Dynavax Technologies Corporation shares last traded at $19.55, with a volume of 1,697,369 shares trading hands.

DVAX has been the subject of several analyst reports. Royal Bank Of Canada restated a “buy” rating and issued a $26.00 target price on shares of Dynavax Technologies Corporation in a report on Friday, September 1st. Zacks Investment Research upgraded Dynavax Technologies Corporation from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a report on Monday, July 10th. BidaskClub cut Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a report on Monday, July 31st. ValuEngine upgraded Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a report on Thursday, September 7th. Finally, Cowen and Company restated an “outperform” rating and issued a $30.00 target price on shares of Dynavax Technologies Corporation in a report on Thursday, August 10th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Dynavax Technologies Corporation currently has an average rating of “Buy” and a consensus target price of $24.80.

The company’s market capitalization is $1.11 billion. The stock’s 50 day moving average is $16.02 and its 200 day moving average is $9.03.

Dynavax Technologies Corporation (NASDAQ:DVAX) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.09. The company had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.15 million. Dynavax Technologies Corporation had a negative return on equity of 92.09% and a negative net margin of 1,323.99%. During the same quarter in the previous year, the firm posted ($0.75) earnings per share. On average, equities analysts anticipate that Dynavax Technologies Corporation will post ($1.58) earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of DVAX. GMT Capital Corp lifted its stake in shares of Dynavax Technologies Corporation by 231.5% during the first quarter. GMT Capital Corp now owns 2,344,500 shares of the biopharmaceutical company’s stock worth $13,950,000 after purchasing an additional 1,637,300 shares in the last quarter. PointState Capital LP acquired a new position in shares of Dynavax Technologies Corporation during the second quarter worth about $13,510,000. Lord Abbett & CO. LLC acquired a new position in shares of Dynavax Technologies Corporation during the second quarter worth about $7,777,000. Point72 Asset Management L.P. acquired a new position in shares of Dynavax Technologies Corporation during the first quarter worth about $4,323,000. Finally, Candriam Luxembourg S.C.A. acquired a new position in shares of Dynavax Technologies Corporation during the second quarter worth about $5,066,000. Institutional investors own 60.23% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/2887170/dynavax-technologies-corporation-dvax-shares-gap-up-to-21-15.html.

About Dynavax Technologies Corporation

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.